Immune Regulation News 8.34 September 16, 2016 | |
| |
TOP STORYDying Tumor Cells Release Intracellular Ions in a Last-Ditch Attempt to Block the Immune System Researchers have discovered how a mineral ion leaked from tumor tissue as it dies acts to stop the work of anti-tumor immune cells. This discovery provides a new approach in the development of treatments to engage the immune system in the fight against cancer. [Press release from the Babraham Institute discussing online prepublication in Nature] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists showed that signal transducer and activator of transcription 3 (STAT3) and STAT1 responses to interleukin-6 (IL-6) are significantly enhanced in CD4 and CD8 T cells from individuals with type 1 diabetes compared to healthy controls. [Sci Transl Med] Abstract To better understand how programmed cell death protein 1 blockade therapy modulates the tumor-host interactions, the authors evaluated three syngeneic murine tumor models, the BRAFV600E-driven YUMM1.1 and YUMM2.1 melanomas, and the carcinogen-induced murine colon adenocarcinoma MC38. [Cancer Immunol Res] Abstract TNFR2 Expression by CD4 Effector T Cells Is Required to Induce Full-Fledged Experimental Colitis To define the role of TNFR2 in the pathogenic CD4 T cells, the authors compared the effect of transferred naïve CD4 cells from WT mice and TNFR2−/− mice into Rag 1−/− recipients. Transfer of TNFR2-deficient effector T cells (Teffs) failed to induce full-fledged colitis, unlike WT Teffs. [Sci Rep] Full Article Scientists examined the transcriptional regulation of fucosyltransferase 7 (FUT7), an enzyme crucial for generation of the glycosylated E- and P-ligs. They found that high expression of the coding gene fut7 in murine CD4+ T cells correlates with DNA demethylation within a minimal promoter in skin/inflammation-seeking effector memory T cells. [J Immunol] Abstract IFN-β + neuroantigen in Alum vaccination elicited elevated numbers and percentages of FOXP3+ T cells in blood and secondary lymphoid organs in 2D2 MOG-specific transgenic mice, and repeated boosters facilitated generation of activated CD44high CD25+ regulatory T cell populations. [J Immunol] Abstract Researchers assessed the effect of sinomenine on the generation and function of regulatory T-cells (Treg) cells in autoimmune arthritis, and the underlying mechanisms in view of aryl hydrocarbon receptor. The proportions of Treg cells and IL-17-producing T-cells differentiated from naive T-cells were analyzed by flow cytometric analysis. [Lab Invest] Abstract Scientists investigated the colitogenic capacity of Scd1KO effector T cells by employing the adoptive T-cell transfer colitis model. Splenic effector T-cells from age- and sex-matched WT and Scd1KO mice were isolated by FACS and intraperitoneally administered to Rag1KO mice, which were monitored for the development of colitis. [Am J Physiol Gastrointest Liver Physiol] Abstract Investigators showed that peroxisome proliferator-activated receptor-alpha deficiency impaired the suppressive activity of regulatory T cells on CD4+CD25− and CD8+ T cell proliferation. [Biochimie] Abstract Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News. | |
| |
REVIEWSInduced Regulatory T Cells: Their Development, Stability, and Applications The authors review the current knowledge on the development of peripheral regulatory T cells (Tregs), induced Tregs, and their roles and applications. [Trends Immunol] Abstract Visit our reviews page to see a complete list of reviews in the immune regulation research field. | |
| |
INDUSTRY NEWSJanssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorization in the European Union for the use of STELARA® for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor alpha antagonist or have medical contraindications to such therapies. [Janssen-Cilag International NV] Press Release Celyad Completes the NKR-2 Phase I Trial with Successful Safety Follow-Up of the Fourth Dose Level Celyad announced the successful completion of the 21-day safety follow-up of the last patient enrolled at the fourth dose level in its Phase I clinical trial evaluating the safety and feasibility of its NKR-2 T-cell therapy – in acute myeloid leukemia and multiple myeloma patients. [Celyad] Press Release Xencor Initiates Phase Ib Trial of Subcutaneous Formulation of XmAb7195 Xencor, Inc. announced that the first patient has been dosed in a Phase Ib multi-dose trial of subcutaneously administered XmAb®7195, a potential treatment for allergic disease. [Xencor, Inc.] Press Release | |
| |
POLICY NEWSNIH Aims to Beef Up Clinical Trial Design as Part of New Data Sharing Rules Drug companies and academic researchers will have to step up their public reporting of clinical trial results under new federal policies. The National Institutes of Health (NIH) also laid out a new plan for submitting clinical trial proposals that aims to beef up the rigor of the studies. [Science Insider] Editorial Europe Proposes Copyright Reform to Help Scientists Mine Research Papers The European Commission has announced long-awaited plans to make it easier for researchers to harvest facts and data from research papers — by freeing the computer-aided activity from the shackles of copyright law. [Nature News] Editorial Illusory Fears Must Not Stifle Chimera Research After more than a decade of controversy, the United States is nudging towards approving research on human–animal embryos. The National Institutes of Health closed a month-long public consultation on ‘chimera research’, and is widely expected to lift a moratorium that forbids federal funding for such work. [Nature News] Editorial Report Urges Trump, Clinton to Make Room for Science in the White House A new report on how the next U.S. president should manage the nation’s science portfolio comes with an invisible sticker on its cover: Open and read immediately if Donald Trump is elected. [Science Insider] Editorial
| |
EVENTSNEW Keystone Symposium: Inflammation-Driven Cancer: Mechanisms to Therapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Opportunities – Immunology (Keck School of Medicine) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.) Professor – Clinical Immunology (Lund University) Postdoctoral Fellow – Immunology (Icahn School of Medicine at Mount Sinai) Postdoctoral Fellow – Molecular Immunology (University of California, San Diego) Chair – Medical Biology (Masaryk University) Postdoctoral Fellow – Genomics and Human Immunity (The Jackson Laboratory) Postdoctoral Researcher – Translational Immunology (University of Eastern Finland) Faculty Position – Immunology (Vanderbilt University Medical Center) Postdoctoral Fellow – Mucosal Immunology (University of Utah) Postdoctoral Position – Tumor Immunology and T Cell Differentiation (University of Lausanne) Postdoctoral Research Scientist (National Taiwan University) Postdoctoral Position – Tumor Immunology (Roswell Park Cancer Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Immune Regulation News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|